Phased Acquisition of Daiichi Sankyo Espha Co., Ltd. and Integration of the Pharmaceutical Business
First written in FY2024-Q1. 4 of 6 entries say "Advanced", first in FY2024-Q2. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「In April 2025, the company additionally acquired a 29% stake in Daiichi Sankyo Espha Co., Ltd., increasing its ownership stake to 80%.」
We acquired an additional 29% in April 2025, making Daiichi Sankyo Espha Co., Ltd. a consolidated subsidiary with an 80% shareholding and advancing the phased acquisition. - FY2025-H1AdvancedAnnual report
「For the interim consolidated accounting period, our Group's consolidated results included revenue of ¥124,771 million, up 40.9% year on year, following Daiichi Sankyo Espha Co., Ltd.'s transition to a consolidated subsidiary with a 51% shareholding. In August 2024, we began providing information on the first large-scale AG products launched since the company joined the Group, “Rivaroxaban Tablets (originator product: Xarelto® Tablets)” and “Rivaroxaban OD Tablets (originator product: Xarelto® OD Tablets),” and obtained marketing approvals for 2 new AG products, “Loxoprofen Na Tape (originator product: Loxonin® Tape)” and “Hydroxychloroquine Sulfate Tablets (originator product: Plaquenil® Tablets).”」
After making Daiichi Sankyo Espha Co., Ltd. a consolidated subsidiary with a 51% shareholding, we began providing information on the first large-scale AG products since it joined the Group and obtained marketing approvals for 2 products. - FY2024AdvancedAnnual report
「In May 2023, we resolved to acquire all shares of Daiichi Sankyo Espha Co., Ltd. in stages, acquired 30% of the shares in October 2023 and an additional 21% in April 2024, and made the company a consolidated subsidiary.」
For Daiichi Sankyo Espha Co., Ltd., following the acquisition of 30% in October 2023, we acquired an additional 21% in April 2024, bringing the voting rights ratio to 51%, and made it a consolidated subsidiary. - FY2024-Q3RestatedAnnual report
「Even in this rapidly changing business environment, our Group aims to remain the company closest to patients. To achieve our medium-term goals in the post-COVID era, we have adopted three key themes, “expansion of scale,” “profit maximization,” and “digitalization,” and are addressing them across all businesses. In May 2023, we resolved to acquire all shares of Daiichi Sankyo Espha Co., Ltd. in stages, and completed the acquisition of 30% of its shares as the first stage in October 2023.」
For Daiichi Sankyo Espha Co., Ltd., it states that the first-stage acquisition of 30% was completed in October 2023 and that the company became an equity-method affiliate. Preparations for integration and acceptance after the acquisition are also continuing. - FY2024-Q2AdvancedAnnual report
「Even in this rapidly changing business environment, our Group aims to remain the company closest to patients. To achieve our medium-term goals in the post-COVID era, we have adopted three key themes, “expansion of scale,” “profit maximization,” and “digitalization,” and are addressing them across all businesses. In May 2023, we resolved to acquire all shares of Daiichi Sankyo Espha Co., Ltd. in stages, and completed the acquisition of 30% of its shares as the first stage in October 2023.」
For the phased acquisition of Daiichi Sankyo Espha Co., Ltd., we completed the first-stage acquisition of 30% on 1 October 2023. The plan to acquire all shares is moving into the execution phase. - FY2024-Q1First statedAnnual report
「At a meeting of the Board of Directors held on 16 May 2023, we resolved to acquire all shares of Daiichi Sankyo Espha Co., Ltd. in stages and entered into a share transfer agreement on the same date. The purpose of this acquisition is to contribute to healthcare and business growth by sharing information and know-how with Daiichi Sankyo Espha Co., Ltd. and our Group, developing high-value-added pharmaceuticals, and creating products that meet customer needs, centered on AG products. 1 October 2023: Shares acquired, 5,400 shares (voting rights ratio: 30%). 1 April 2024: Shares acquired, 3,780 shares (voting rights ratio: 51%). Shares held after acquiring all shares: 18,000 shares (voting rights ratio: 100%). Acquisition cost after acquiring all shares: ¥25,000 million.」
In May 2023, we resolved to acquire the shares in stages and entered into a share transfer agreement. We acquired 30% in October 2023 and 51% in April 2024. The timing of acquiring the remaining 49% was to be discussed separately, and the acquisition cost after acquiring all shares was ¥25,000 million. We aim to integrate the businesses by sharing information and know-how, developing products centered on AG products, ensuring stable supply, and expanding the profitability of healthcare-related businesses.